| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteoporosis | 20 | 2020 | 241 | 3.550 |
Why?
|
| Malnutrition | 6 | 2020 | 218 | 3.300 |
Why?
|
| Fractures, Bone | 13 | 2018 | 291 | 2.610 |
Why?
|
| Osteoporotic Fractures | 7 | 2020 | 37 | 2.060 |
Why?
|
| Geriatric Assessment | 9 | 2020 | 275 | 1.950 |
Why?
|
| Nutrition Assessment | 5 | 2020 | 169 | 1.680 |
Why?
|
| Bone Density Conservation Agents | 9 | 2019 | 198 | 1.660 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 9 | 2017 | 91 | 1.620 |
Why?
|
| Diphosphonates | 7 | 2016 | 262 | 1.550 |
Why?
|
| Osteoporosis, Postmenopausal | 5 | 2013 | 37 | 1.320 |
Why?
|
| Neoplasms | 18 | 2020 | 15193 | 1.220 |
Why?
|
| Accidental Falls | 7 | 2017 | 142 | 1.130 |
Why?
|
| Femoral Fractures | 3 | 2016 | 50 | 1.110 |
Why?
|
| Bone Density | 13 | 2020 | 476 | 1.040 |
Why?
|
| Hip Fractures | 4 | 2011 | 76 | 0.990 |
Why?
|
| Osteonecrosis | 3 | 2008 | 53 | 0.960 |
Why?
|
| Vitamin D Deficiency | 3 | 2019 | 115 | 0.800 |
Why?
|
| Fractures, Spontaneous | 2 | 2011 | 84 | 0.740 |
Why?
|
| Frailty | 2 | 2019 | 113 | 0.740 |
Why?
|
| Gadolinium | 3 | 2014 | 164 | 0.680 |
Why?
|
| Aged, 80 and over | 28 | 2020 | 29902 | 0.670 |
Why?
|
| Wrist Injuries | 2 | 2010 | 12 | 0.660 |
Why?
|
| Jaw Diseases | 2 | 2008 | 21 | 0.660 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 2 | 2014 | 10 | 0.620 |
Why?
|
| Spinal Fractures | 3 | 2020 | 132 | 0.610 |
Why?
|
| Thiazides | 1 | 2017 | 6 | 0.610 |
Why?
|
| Aged | 40 | 2020 | 70117 | 0.600 |
Why?
|
| Cognitive Dysfunction | 2 | 2019 | 333 | 0.560 |
Why?
|
| Risk Factors | 20 | 2020 | 17523 | 0.560 |
Why?
|
| Dementia | 2 | 2019 | 453 | 0.560 |
Why?
|
| Activities of Daily Living | 1 | 2019 | 552 | 0.550 |
Why?
|
| United States Food and Drug Administration | 8 | 2013 | 332 | 0.540 |
Why?
|
| Product Surveillance, Postmarketing | 5 | 2013 | 42 | 0.540 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2017 | 151 | 0.540 |
Why?
|
| Mass Screening | 2 | 2019 | 1509 | 0.520 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2017 | 193 | 0.520 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 257 | 0.520 |
Why?
|
| Pharmacovigilance | 1 | 2014 | 12 | 0.510 |
Why?
|
| Anilides | 1 | 2017 | 268 | 0.510 |
Why?
|
| Postmenopause | 3 | 2018 | 378 | 0.490 |
Why?
|
| Body Mass Index | 2 | 2019 | 2203 | 0.490 |
Why?
|
| Depressive Disorder, Major | 1 | 2019 | 441 | 0.460 |
Why?
|
| Endocrine System | 1 | 2013 | 36 | 0.450 |
Why?
|
| Antineoplastic Agents | 10 | 2019 | 14289 | 0.440 |
Why?
|
| Female | 46 | 2020 | 141928 | 0.440 |
Why?
|
| Dental Care for Chronically Ill | 3 | 2011 | 11 | 0.440 |
Why?
|
| Menopause | 1 | 2013 | 159 | 0.430 |
Why?
|
| Humans | 66 | 2020 | 261506 | 0.400 |
Why?
|
| Contrast Media | 2 | 2014 | 1472 | 0.380 |
Why?
|
| Secondary Prevention | 2 | 2016 | 329 | 0.380 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2011 | 84 | 0.380 |
Why?
|
| Male | 33 | 2020 | 123000 | 0.370 |
Why?
|
| Pyridines | 1 | 2017 | 1244 | 0.360 |
Why?
|
| Jaw | 1 | 2008 | 20 | 0.340 |
Why?
|
| Electronic Health Records | 2 | 2017 | 929 | 0.320 |
Why?
|
| Absorptiometry, Photon | 4 | 2015 | 239 | 0.320 |
Why?
|
| Surveys and Questionnaires | 2 | 2017 | 5687 | 0.300 |
Why?
|
| Prevalence | 5 | 2020 | 3260 | 0.300 |
Why?
|
| Liver | 1 | 2017 | 2961 | 0.290 |
Why?
|
| Emigrants and Immigrants | 1 | 2009 | 147 | 0.290 |
Why?
|
| Ulna Fractures | 1 | 2006 | 7 | 0.290 |
Why?
|
| Health Education | 1 | 2009 | 309 | 0.280 |
Why?
|
| Radius Fractures | 1 | 2006 | 16 | 0.280 |
Why?
|
| Aging | 5 | 2013 | 1582 | 0.280 |
Why?
|
| Middle Aged | 26 | 2020 | 86204 | 0.280 |
Why?
|
| Incidence | 7 | 2017 | 5673 | 0.270 |
Why?
|
| Illinois | 3 | 2015 | 24 | 0.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2014 | 598 | 0.270 |
Why?
|
| Retrospective Studies | 11 | 2020 | 37905 | 0.260 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 739 | 0.260 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2012 | 1209 | 0.260 |
Why?
|
| United States | 16 | 2020 | 15433 | 0.250 |
Why?
|
| Weight Loss | 2 | 2019 | 627 | 0.240 |
Why?
|
| Comorbidity | 3 | 2019 | 2352 | 0.220 |
Why?
|
| Proportional Hazards Models | 4 | 2020 | 4988 | 0.220 |
Why?
|
| Chicago | 3 | 2009 | 40 | 0.210 |
Why?
|
| Postural Balance | 4 | 2013 | 151 | 0.210 |
Why?
|
| Case-Control Studies | 3 | 2019 | 6100 | 0.200 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 399 | 0.200 |
Why?
|
| Databases, Factual | 3 | 2020 | 2218 | 0.200 |
Why?
|
| Patient Education as Topic | 3 | 2012 | 748 | 0.190 |
Why?
|
| Lumbar Vertebrae | 3 | 2020 | 245 | 0.190 |
Why?
|
| Skin Neoplasms | 1 | 2017 | 4654 | 0.180 |
Why?
|
| Women's Health | 2 | 2018 | 205 | 0.180 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 4557 | 0.180 |
Why?
|
| Orthopedics | 1 | 2020 | 66 | 0.180 |
Why?
|
| Walking Speed | 1 | 2019 | 17 | 0.170 |
Why?
|
| Healthy Lifestyle | 1 | 2019 | 44 | 0.170 |
Why?
|
| Program Development | 3 | 2012 | 261 | 0.170 |
Why?
|
| RANK Ligand | 2 | 2017 | 119 | 0.170 |
Why?
|
| Nutritional Support | 1 | 2019 | 80 | 0.160 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 140 | 0.160 |
Why?
|
| Primary Health Care | 1 | 2004 | 787 | 0.160 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 175 | 0.160 |
Why?
|
| Geriatrics | 1 | 2019 | 98 | 0.160 |
Why?
|
| Focus Groups | 2 | 2012 | 256 | 0.160 |
Why?
|
| Nutritional Status | 1 | 2020 | 337 | 0.160 |
Why?
|
| Risk Reduction Behavior | 1 | 2019 | 227 | 0.160 |
Why?
|
| Drug Approval | 2 | 2009 | 178 | 0.160 |
Why?
|
| Survival Analysis | 2 | 2020 | 9180 | 0.160 |
Why?
|
| Walking | 2 | 2013 | 277 | 0.150 |
Why?
|
| Receptor Activator of Nuclear Factor-kappa B | 1 | 2017 | 46 | 0.150 |
Why?
|
| Logistic Models | 4 | 2017 | 3441 | 0.150 |
Why?
|
| Adult | 14 | 2019 | 77950 | 0.150 |
Why?
|
| Cause of Death | 1 | 2020 | 752 | 0.150 |
Why?
|
| Risk Assessment | 7 | 2019 | 6869 | 0.150 |
Why?
|
| Imidazoles | 2 | 2016 | 999 | 0.150 |
Why?
|
| Prospective Studies | 8 | 2017 | 12873 | 0.140 |
Why?
|
| Breast Neoplasms | 3 | 2017 | 15694 | 0.140 |
Why?
|
| Texas | 2 | 2017 | 6311 | 0.140 |
Why?
|
| Hematologic Neoplasms | 1 | 2007 | 1870 | 0.130 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2015 | 36 | 0.130 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 1996 | 163 | 0.130 |
Why?
|
| Amyloid | 1 | 1996 | 97 | 0.130 |
Why?
|
| Cancer Survivors | 2 | 2019 | 650 | 0.130 |
Why?
|
| Gray Matter | 1 | 2015 | 63 | 0.130 |
Why?
|
| Meglumine | 1 | 2014 | 20 | 0.130 |
Why?
|
| Biomarkers | 3 | 2019 | 5047 | 0.130 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2015 | 105 | 0.130 |
Why?
|
| Kidney Diseases | 2 | 2012 | 691 | 0.120 |
Why?
|
| Hypotension | 1 | 1996 | 210 | 0.120 |
Why?
|
| Hospitals | 1 | 2017 | 485 | 0.120 |
Why?
|
| Heterocyclic Compounds | 1 | 2014 | 119 | 0.120 |
Why?
|
| Gadolinium DTPA | 1 | 2014 | 172 | 0.120 |
Why?
|
| Registries | 3 | 2020 | 2170 | 0.120 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2017 | 272 | 0.120 |
Why?
|
| Mandatory Reporting | 1 | 2013 | 24 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 4971 | 0.120 |
Why?
|
| Calcium | 2 | 2012 | 1537 | 0.120 |
Why?
|
| Organometallic Compounds | 1 | 2014 | 191 | 0.120 |
Why?
|
| C-Reactive Protein | 1 | 2017 | 527 | 0.120 |
Why?
|
| Perimenopause | 1 | 2013 | 3 | 0.110 |
Why?
|
| Drug Information Services | 1 | 2013 | 11 | 0.110 |
Why?
|
| Fracture Healing | 1 | 2013 | 40 | 0.110 |
Why?
|
| Drug Labeling | 1 | 2013 | 29 | 0.110 |
Why?
|
| Hot Flashes | 1 | 2013 | 37 | 0.110 |
Why?
|
| Motor Skills | 1 | 2013 | 107 | 0.110 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 313 | 0.110 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2013 | 110 | 0.110 |
Why?
|
| Age Factors | 6 | 2018 | 5377 | 0.110 |
Why?
|
| Anaphylaxis | 1 | 2013 | 119 | 0.110 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 4298 | 0.100 |
Why?
|
| Bisphosphonate-Associated Osteonecrosis of the Jaw | 1 | 2011 | 13 | 0.100 |
Why?
|
| Amiodarone | 1 | 2012 | 42 | 0.100 |
Why?
|
| Bayes Theorem | 2 | 2013 | 1021 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 6009 | 0.100 |
Why?
|
| Academic Medical Centers | 2 | 2005 | 672 | 0.100 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 205 | 0.100 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 702 | 0.090 |
Why?
|
| Optic Nerve Diseases | 1 | 2012 | 103 | 0.090 |
Why?
|
| Cohort Studies | 3 | 2017 | 9244 | 0.090 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2012 | 226 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2019 | 1423 | 0.090 |
Why?
|
| Point-of-Care Systems | 1 | 2012 | 196 | 0.090 |
Why?
|
| Orphan Drug Production | 1 | 2009 | 10 | 0.090 |
Why?
|
| Interviews as Topic | 1 | 2011 | 497 | 0.090 |
Why?
|
| Professional Staff Committees | 1 | 2009 | 30 | 0.090 |
Why?
|
| American Dental Association | 1 | 2008 | 1 | 0.090 |
Why?
|
| Precipitating Factors | 1 | 2008 | 6 | 0.090 |
Why?
|
| Tooth Extraction | 1 | 2008 | 11 | 0.090 |
Why?
|
| Dental Care | 1 | 2008 | 15 | 0.090 |
Why?
|
| Physical Therapy Modalities | 1 | 2009 | 95 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 1 | 2012 | 602 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2012 | 294 | 0.080 |
Why?
|
| Aromatase Inhibitors | 1 | 2011 | 305 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 1323 | 0.080 |
Why?
|
| Femur Neck | 1 | 2008 | 23 | 0.080 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2008 | 24 | 0.080 |
Why?
|
| Hip | 1 | 2008 | 28 | 0.080 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 4314 | 0.080 |
Why?
|
| Hyperthyroidism | 1 | 2008 | 52 | 0.080 |
Why?
|
| Calcitonin | 1 | 2008 | 186 | 0.080 |
Why?
|
| Biomechanical Phenomena | 2 | 2013 | 338 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 1 | 2015 | 3981 | 0.070 |
Why?
|
| China | 1 | 2009 | 606 | 0.070 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2017 | 1215 | 0.070 |
Why?
|
| Exercise | 2 | 2019 | 1183 | 0.070 |
Why?
|
| Hematinics | 1 | 2008 | 109 | 0.070 |
Why?
|
| Drug Industry | 1 | 2007 | 88 | 0.070 |
Why?
|
| Disease Management | 1 | 2012 | 1052 | 0.070 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2008 | 145 | 0.070 |
Why?
|
| Self Efficacy | 1 | 2009 | 298 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2008 | 205 | 0.070 |
Why?
|
| Calcaneus | 1 | 2006 | 17 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 4892 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 7702 | 0.070 |
Why?
|
| Analgesics | 1 | 2009 | 390 | 0.070 |
Why?
|
| Prognosis | 2 | 2017 | 21713 | 0.070 |
Why?
|
| Algorithms | 1 | 2017 | 3890 | 0.070 |
Why?
|
| Vitamin D | 1 | 2008 | 261 | 0.070 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 1382 | 0.070 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2004 | 1303 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 543 | 0.070 |
Why?
|
| Attitude to Health | 1 | 2009 | 465 | 0.070 |
Why?
|
| Quality of Life | 1 | 2019 | 4532 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 918 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 3251 | 0.060 |
Why?
|
| Survivors | 1 | 2011 | 1031 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1362 | 0.060 |
Why?
|
| Disease Progression | 1 | 2016 | 6682 | 0.060 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 233 | 0.060 |
Why?
|
| Quality Improvement | 1 | 2012 | 851 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2008 | 1544 | 0.060 |
Why?
|
| Health Behavior | 1 | 2009 | 603 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2006 | 245 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2012 | 1054 | 0.060 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 3001 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2011 | 3005 | 0.060 |
Why?
|
| Health Services for the Aged | 1 | 2003 | 50 | 0.060 |
Why?
|
| Radiography | 1 | 2008 | 1904 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 945 | 0.060 |
Why?
|
| Venous Thromboembolism | 1 | 2008 | 335 | 0.060 |
Why?
|
| Continuity of Patient Care | 1 | 2005 | 225 | 0.060 |
Why?
|
| Hospitalization | 1 | 2012 | 2083 | 0.050 |
Why?
|
| Primary Prevention | 1 | 2004 | 255 | 0.050 |
Why?
|
| Anemia | 1 | 2008 | 689 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2007 | 674 | 0.050 |
Why?
|
| Health Services Accessibility | 2 | 2007 | 761 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2013 | 2138 | 0.050 |
Why?
|
| Diagnostic Imaging | 1 | 2009 | 1162 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2017 | 10331 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 5437 | 0.050 |
Why?
|
| Clinical Trials as Topic | 4 | 2013 | 3719 | 0.050 |
Why?
|
| Perception | 1 | 2002 | 350 | 0.050 |
Why?
|
| Diagnosis, Differential | 1 | 2009 | 4744 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2003 | 2803 | 0.040 |
Why?
|
| Melanoma | 1 | 2017 | 5317 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2006 | 1863 | 0.040 |
Why?
|
| Thoracic Vertebrae | 1 | 2020 | 186 | 0.040 |
Why?
|
| Cervical Vertebrae | 1 | 2020 | 205 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2019 | 32848 | 0.040 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 2403 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 3578 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 14889 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2009 | 447 | 0.040 |
Why?
|
| Islet Amyloid Polypeptide | 1 | 1996 | 16 | 0.030 |
Why?
|
| Pancreatic Neoplasms | 1 | 2013 | 5061 | 0.030 |
Why?
|
| Osmolar Concentration | 1 | 1996 | 204 | 0.030 |
Why?
|
| Consensus | 1 | 2019 | 978 | 0.030 |
Why?
|
| ROC Curve | 1 | 2018 | 1183 | 0.030 |
Why?
|
| Time Factors | 3 | 2019 | 12926 | 0.030 |
Why?
|
| Osteomalacia | 1 | 1994 | 36 | 0.030 |
Why?
|
| Advisory Committees | 1 | 2016 | 203 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 6207 | 0.030 |
Why?
|
| Ethics Committees, Research | 1 | 2013 | 40 | 0.030 |
Why?
|
| Overweight | 1 | 2017 | 484 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 1945 | 0.030 |
Why?
|
| Independent Living | 1 | 2013 | 73 | 0.030 |
Why?
|
| Contraindications | 1 | 2012 | 150 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2013 | 495 | 0.030 |
Why?
|
| Oral Hygiene | 1 | 2011 | 20 | 0.030 |
Why?
|
| Age Distribution | 1 | 2013 | 698 | 0.030 |
Why?
|
| Oral Surgical Procedures | 1 | 2011 | 32 | 0.030 |
Why?
|
| Blindness | 1 | 2012 | 77 | 0.030 |
Why?
|
| Denosumab | 1 | 2011 | 68 | 0.020 |
Why?
|
| Blood Glucose | 1 | 1996 | 1244 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 482 | 0.020 |
Why?
|
| Collagen Type I | 1 | 2011 | 204 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 2139 | 0.020 |
Why?
|
| Blood Pressure | 1 | 1996 | 1467 | 0.020 |
Why?
|
| Glucose | 1 | 1996 | 1248 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2013 | 938 | 0.020 |
Why?
|
| Patient Care Planning | 1 | 2011 | 297 | 0.020 |
Why?
|
| Drug Utilization Review | 1 | 2009 | 36 | 0.020 |
Why?
|
| Pulmonary Edema | 1 | 2009 | 80 | 0.020 |
Why?
|
| Torque | 1 | 2008 | 18 | 0.020 |
Why?
|
| Rotation | 1 | 2008 | 112 | 0.020 |
Why?
|
| Darbepoetin alfa | 1 | 2008 | 26 | 0.020 |
Why?
|
| Fee-for-Service Plans | 1 | 2007 | 40 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2015 | 2594 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2007 | 306 | 0.020 |
Why?
|
| Peptides | 1 | 2011 | 1479 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 10001 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2009 | 1665 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2007 | 256 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 2055 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2007 | 272 | 0.020 |
Why?
|
| Benzamides | 1 | 2009 | 1832 | 0.010 |
Why?
|
| Risk | 1 | 2008 | 1972 | 0.010 |
Why?
|
| Nurse Practitioners | 1 | 2003 | 63 | 0.010 |
Why?
|
| Medicare | 1 | 2007 | 860 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 2927 | 0.010 |
Why?
|
| Reaction Time | 1 | 2002 | 234 | 0.010 |
Why?
|
| Education, Medical, Continuing | 1 | 2003 | 251 | 0.010 |
Why?
|
| Posture | 1 | 2002 | 215 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2017 | 8873 | 0.010 |
Why?
|
| Probability | 1 | 2002 | 866 | 0.010 |
Why?
|
| Piperazines | 1 | 2009 | 2101 | 0.010 |
Why?
|
| Movement | 1 | 2002 | 556 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2011 | 4367 | 0.010 |
Why?
|
| Referral and Consultation | 1 | 2003 | 899 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2009 | 3518 | 0.010 |
Why?
|
| Heart Failure | 1 | 2009 | 2516 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 12221 | 0.010 |
Why?
|
| Adolescent | 1 | 2013 | 31252 | 0.010 |
Why?
|
| Child | 1 | 2013 | 29154 | 0.010 |
Why?
|